Efficacy of Intracavernosal Injections of 50-Unit versus 100-Unit Doses of AbobotulinumtoxinA (Masport®) in Vasculogenic Erectile Dysfunction with Phosphodiesterase Type 5 Inhibitors Resistant

Background: We aimed to evaluate the safety and efficacy of 50-unit dose against 100-unit dose of intracavernosal injection (ICI) of AbobotulinumtoxinA (BTX-A) (Masport®) in patients with vascular erectile dysfunction (ED) resistant to first-line therapies, including phosphodiesterase type 5 inhibitors (PDE5I). Methods: In this double-blind randomized controlled trial (RCT), 40 patients with ED resistant to PDE5I were randomly divided into two groups: ICI of a single dose of Masport® 50 units and single dose of 100 units. Peak systolic velocity (PSV) confirmed arterial insufficiency vascular disorder. For all patients, IIEF (International Index of Erectile Function), SHIM (Sexual Health Inventory for Men), and EHS (Erection Hardness Score) questionnaires were completed. Six weeks after the treatment, the subjects were re-examined. Results: Our results showed an acceptable clinical efficacy and safety of ICI of Masport® six weeks after injection. No systemic complications in patients were seen. Three patients complained of brief penile pain shortly after injection, but there were no other local complications. The increase in mean PSV in the 100-unit group due to treatment was significant (P-value < 0.0001). Also, there was a significant difference between the two groups of 50- and 100-unit (P-value < 0.0001). In addition, the increase in mean IIEF-EF, SHIM score, and EHS due to treatment was significant between the two groups. For the 100-unit group, P-value < 0.0001 and the difference between the two groups was also significant (P-value < 0.0001), which indicated a better response to treatment in the 100-unit group. The mean increase of IIEF score (EF domain) was 4.3 (mean IIEF: 9.4 and 13.7 after and before, respectively) in the 100-unit group and (mean IIEF: 8.1 and 9.1 after and before, respectively) in the 50-unit group. Conclusions: The results of this study showed that ICI of AbobotulinumtoxinA, especially at a dose of 100 units, in patients with refractory vasculogenic ED is safe and effective in improving sexual function and ultrasound indices.

Download Full-text

Faculty Opinions recommendation of The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1157814.7467056 ◽

2010 ◽

Author(s):

Apostolos Apostolidis

Keyword(s):

Erectile Dysfunction ◽

Urinary Tract ◽

Lower Urinary Tract Symptoms ◽

Lower Urinary Tract ◽

Phosphodiesterase Type 5 Inhibitors ◽

Urinary Tract Symptoms ◽

Phosphodiesterase Type ◽

The Relationship ◽

Lower Urinary

Download Full-text

Faculty of 1000 evaluation for Effects of once-daily tadalafil on treatment satisfaction, psychosocial outcomes, spontaneous erections, and measures of endothelial function in men with erectile dysfunction but naive to phosphodiesterase type 5 inhibitors.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.717967684.793467351 ◽

2012 ◽

Author(s):

Chiara Simonelli ◽

Roberta Rossi

Keyword(s):

Erectile Dysfunction ◽

Endothelial Function ◽

Treatment Satisfaction ◽

Psychosocial Outcomes ◽

Phosphodiesterase Type 5 Inhibitors ◽

Once Daily ◽

Phosphodiesterase Type

Download Full-text

Is there a role for extracorporeal shock wave therapy for erectile dysfunction unresponsive to phosphodiesterase type 5 inhibitors?

World Journal of Urology ◽

10.1007/s00345-016-1899-y ◽

2016 ◽

Vol 35 (1) ◽

pp. 167-171 ◽

Cited By ~ 1

Author(s):

Zi-jun Zou ◽

Zhi-hong Liu ◽

Liang-you Tang ◽

Yi-ping Lu

Keyword(s):

Shock Wave ◽

Erectile Dysfunction ◽

Extracorporeal Shock Wave Therapy ◽

Shock Wave Therapy ◽

Phosphodiesterase Type 5 Inhibitors ◽

Extracorporeal Shock Wave ◽

Phosphodiesterase Type

Download Full-text

Peculiarities of correction of sexual function in men presenting with diabetes mellitus

Diabetes Mellitus ◽

10.14341/2072-0351-5484 ◽

2010 ◽

Vol 13 (3) ◽

pp. 30-31

Author(s):

Roman Viktorovich Rozhivanov ◽

Alexander Evgen'evich Lepetukhin ◽

Sergey Anatol'evich Dubskiy ◽

Dmitriy Gennad'evich Kurbatov

Keyword(s):

Diabetes Mellitus ◽

Erectile Dysfunction ◽

Sexual Function ◽

Lipoic Acid ◽

Research Centre ◽

Alpha Lipoic Acid ◽

Phosphodiesterase Type 5 Inhibitors ◽

Phosphodiesterase Type

Diabetes mellitus (DM) is frequently associated with disturbances of the sexual function underlain by hypogonadism and neuropathy. These pathologicalconditions are successfully managed by androgens, alpha-lipoic acid, and phosphodiesterase type 5 inhibitors, besides compensation of carbohydratemetabolism. This paper reports results of evaluation of different methods for the treatment of erectile dysfunction in DM patients basedat Endocrinological Research Centre. Their combination ensured higher than 90% efficiency of therapy.

Download Full-text

Drugs

ESC CardioMed ◽

10.1093/med/9780198784906.003.0249 ◽

2018 ◽

pp. 1030-1035

Author(s):

Mike Kirby ◽

Jonny Coxon

Keyword(s):

Quality Of Life ◽

Cardiovascular Disease ◽

Erectile Dysfunction ◽

Negative Effects ◽

Phosphodiesterase Type 5 Inhibitors ◽

Cardiac Condition ◽

Male Patients ◽

Phosphodiesterase Type ◽

The Impact

It should not be presumed that male patients with cardiovascular disease are less sexually active than others, but they are more likely to have erectile dysfunction. It is therefore crucial to consider the impact on sexual function of medications commonly used to treat cardiovascular disease, because negative effects on erectile dysfunction can lead to problems with compliance and quality of life. Cardiovascular implications of phosphodiesterase type 5 inhibitors used to treat erectile dysfunction should be borne in mind. Effective treatment of the cardiac condition should always take priority.

Download Full-text

Impact of undiagnosed prediabetes on phosphodiesterase type 5 inhibitors response in men with erectile dysfunction

European Urology Supplements ◽

10.1016/s1569-9056(19)33579-1 ◽

2019 ◽

Vol 18 (9) ◽

pp. e3216-e3217

Author(s):

L. Boeri ◽

P. Capogrosso ◽

E. Ventimiglia ◽

W. Cazzaniga ◽

E. Pozzi ◽

...

Keyword(s):

Erectile Dysfunction ◽

Phosphodiesterase Type 5 Inhibitors ◽

Phosphodiesterase Type

Download Full-text

Combination Therapy Of Tadalafil And Pentoxifylline In Severe Erectile Dysfunction; A Prospective Randomized Trial

Polish Journal of Surgery ◽

10.1515/pjs-2015-0075 ◽

2015 ◽

Vol 87 (8) ◽

Cited By ~ 2

Author(s):

Santosh Kumar ◽

Rajesh Roat ◽

Swati Agrawal ◽

Kumar Jayant ◽

Ravimohan S. Mavuduru ◽

...

Keyword(s):

Erectile Dysfunction ◽

Combination Therapy ◽

Erectile Function ◽

T Test ◽

P Value ◽

Chi Square ◽

Significant Difference ◽

Chi Square Test ◽

Group A ◽

Group B

Abstractwas to assess efficacy of Tadalafil alone versus Tadalafil plus Pentoxifylline in the treatment of erectile dysfunction by using self administered IIEF-5 questionnaire.Two hundred and thirty seven patients presenting with ED at andrology OPD were evaluated for ED by a self administered IIEF (International Index of Erectile Function) questionnaire. Patients were systematically randomized by computer generated random table into two groups groups namely, group A: Tadalafil only group, group B: combination of Tadalafil + Pentoxifyl-line. All the patients were re-assessed by IIEF-5 questionnaire after 8 weeks of medical therapy. Statistical analysis was performed using student’s unpaired t-test, paired t-test, chi square test. p-value < 0.05 was considered statistically significant.Two hundred and thirty seven patients were included in the present study, in group A: 92 patients (78.6%) showed improvement in their IIEF score after 8 weeks of tadalafil treatment. While in group B, overall 104 patients(86.6%) showed improvement after combination of Tadalafil and Pentoxifylline. There was a statistically significant difference of percentage change in IIEF score was seen in group B (group A 90.7±15.2%, group B 95.6±13.4%; p value – 0.014). We found this difference even more statistically significant in patients with severe ED (group A 72.7±47.2%, group B 132.3±54.3%; p value – 0.000). There was no significant difference in between the two groups with regards to occur-rence of side effects.Both tadalafil and combination of Tadalafil + Pentoxifylline improve erectile function in patients of ED. Patients with severe ED showed much significant improvement in erectile function with combination therapy.

Download Full-text